Precision Health Clinical Trials

Personalized Environment and Genes Study

Conditions:   Diabetes;   Heart Disease;   Asthma
Sponsor:   National Institute of Environmental Health Sciences (NIEHS)

Cough Capture as a Portal Into the Lung

Conditions:   Lung Diseases;   Lung Cancer;   Lung Diseases, Obstructive;   Lung Diseases, Interstitial;   Lung Inflammation
Intervention:   Other: Observational only, all subjects; measure DNA mutation and proteomic survey.
Sponsors:   Albert Einstein College of Medicine;   National Center for Advancing Translational Sciences (NCATS)

Autophagy in Paediatric Crohn's Disease

Conditions:   Crohn Disease;   Pediatric Crohns Disease
Interventions:   Other: Blood samples;   Other: Biopsies
Sponsor:   Hospices Civils de Lyon
Not yet recruiting

Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma

Condition:   Biliary Tract Carcinoma
Intervention:   Diagnostic Test: The extracted DNA from bile samples will be analyzed by BileCAD to determine the level of CIN.
Sponsor:   Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Genetic and Haematological Modifiers of SCD Severity in Kaduna State, Northern Nigeria

Condition:   Sickle Cell Disease
Sponsors:   Ahmadu Bello University Teaching Hospital;   Cyprus Institute of Neurology and Genetics
Not yet recruiting

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Condition:   MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Interventions:   Drug: HRO761;   Biological: tislelizumab;   Drug: irinotecan
Sponsor:   Novartis Pharmaceuticals

Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations

Condition:   Muscular Dystrophy, Duchenne
Intervention:   Diagnostic Test: MUSCLE MAGNETIC RESONANCE IMAGING (MRI)
Sponsor:   Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: sunitinib or pazopanib;   Drug: PD-1 inhibitor combined with axitinib
Sponsors:   RenJi Hospital;   Ruijin Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   West China Hospital;   Xiangya Hospital of Central South University;   Fudan University;   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Second Affiliated Hospital of Nantong University;   Peking University First Hospital;   Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University;   Shanghai Jiao Tong University Affiliated Sixth People's Hospital;   Zhejiang University;   First Affiliated Hospital of Wenzhou Medical University;   Sir Run Run Shaw Hospital;   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School;   The General Hospital of Eastern Theater Command;   The First Affiliated Hospital with Nanjing Medical University;   The First Affiliated Hospital of University of Science and Technology of China;   The Second Hospital of Anhui Medical University;   Tongji Hospital;   The First Affiliated Hospital of Zhengzhou University;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   Peking Union Medical College Hospital;   The First Affiliated Hospital of Shanxi Medical University;   Shanxi Provincial Cancer Hospital;   Changzhi Medical College;   First Affiliated Hospital Xi'an Jiaotong University;   Second Affiliated Hospital of Xi'an Jiaotong University;   Xijing Hospital of Air Force Military Medical University;   Tang-Du Hospital;   Quanzhou First Hospital Affiliated to Fujian Medical University;   Third Affiliated Hospital, Sun Yat-Sen University

The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck

Condition:   Head and Neck Cancer
Intervention:   Genetic: Molecular Analyses
Sponsor:   Royal Marsden NHS Foundation Trust
Not yet recruiting

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Castration-Resistant Prostate Carcinoma;   Stage IVB Prostate Cancer AJCC v8
Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Biological: Magrolimab;   Drug: Olaparib
Sponsor:   National Cancer Institute (NCI)